RA patients are receiving recommended cancer screenings

Share this article:
RA Patients Are Receiving Recommended Cancer Screenings
RA Patients Are Receiving Recommended Cancer Screenings

(HealthDay News) -- Patients with rheumatoid arthritis (RA) receive cancer screening tests at higher rates than that of the general population, according to a study published online July 10 in Arthritis & Rheumatism.

Using data from a large U.S. commercial insurance plan, Seoyoung C. Kim, M.D., from Brigham and Women's Hospital in Boston, and colleagues compared cancer screening rates for patients with and without RA. RA was identified as two or more diagnoses of RA and at least one prescription for a disease-modifying anti-rheumatic drug.

The researchers found that, over a mean of 2.3 years of follow-up, both RA and non-RA patients were screened, on average, once every three years for cervical cancer and once every two years for breast cancer. Adjusting for age, women with RA were more likely than non-RA patients to receive one or more of each of the following tests: Papanicolaou smear (hazard ratio [HR], 1.21; 95 percent confidence interval [CI], 1.17 to 1.24), mammogram (HR, 1.49; 95 percent CI, 1.45 to 1.53), and colonoscopy (HR, 1.69; 95 percent CI, 1.61 to 1.77). Similarly, men with RA were more likely than non-RA patients to receive a colonoscopy (HR, 1.52; 95 percent CI, 1.40 to 1.64). These results persisted when adjusting for age, number of physician visits, percent of visits made to primary care physicians, and comorbidity index.

"Individuals with RA did not appear to be at risk for receiving fewer cancer screening tests than non-RA patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

ACCR: Oral olaparib with chemotherapy beneficial for ovarian ...

Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.

Meta-Analysis: Prediabetes tied to increased risk of cancer

Meta-Analysis: Prediabetes tied to increased risk of cancer

Prediabetes has been linked to an increased risk of cancer overall and with increased risks of site-specific cancers, including liver, endometrial, and stomach/colorectal cancer.

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.